证券代码：603387 证券简称：基蛋生物 公告编号：2023-012 基蛋生物科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 05 月 18 日上午 09:00-10:00 会议召开时间：2023年05月18日(星期四)上午09:00-10:00 会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 投资者可于2023年05月11日(星期四)至05月17日(星期三)16:00前登录 上证路演中心网站首页点击"提问预 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥403,956,352.10, representing a year-on-year increase of 25.50%[3] - The net profit attributable to shareholders for Q3 2022 was ¥145,399,343.30, reflecting a significant increase of 76.76% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥135,619,425.05, up by 83.96% year-on-year[3] - For the first three quarters of 2022, the company achieved a total revenue of 1.377 billion RMB, representing a year-over-year growth of 49.34%[11] - The net profit attributable to shareholders for the same period was 475 million RMB, an increase of 87.74% compared to the previous year[11] - Net profit for the first three quarters of 2022 was ¥481,071,216.93, representing a 83.5% increase from ¥262,123,493.95 in the same period of 2021[20] - The company reported a total comprehensive income of ¥481,643,628.87 for the third quarter of 2022, compared to ¥262,121,862.08 in the same quarter of 2021[21] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date period increased by 113.33% to ¥207,880,331.23[3] - The net cash flow from operating activities for Q3 2022 was ¥207,880,331.23, an increase from ¥97,446,913.82 in Q3 2021, representing a growth of approximately 113%[24] - Total cash inflow from operating activities amounted to ¥1,456,238,026.02, compared to ¥1,106,288,768.88 in the previous year, indicating a year-over-year increase of about 32%[24] - Cash outflow from operating activities was ¥1,248,357,694.79, up from ¥1,008,841,855.06, reflecting a rise of approximately 24%[24] - The company’s cash and cash equivalents as of September 30, 2022, amounted to approximately 1.135 billion RMB, up from 968.9 million RMB at the end of 2021[15] - The cash and cash equivalents at the end of the period reached ¥1,133,577,261.76, up from ¥939,447,825.95 at the end of Q3 2021, representing an increase of approximately 21%[25] Assets and Equity - The total assets at the end of the reporting period were ¥3,654,181,309.98, a growth of 16.45% from the end of the previous year[4] - The equity attributable to shareholders at the end of the reporting period was ¥2,458,822,357.52, marking a 16.73% increase year-on-year[4] - Total assets as of September 30, 2022, were approximately 3.654 billion RMB, compared to 3.138 billion RMB at the end of 2021[16] - Total equity reached ¥2,641,369,078.62, up from ¥2,274,029,770.25 in the same period of 2021[18] Research and Development - Research and development investment for the first three quarters reached 170 million RMB, a year-over-year increase of 30.17%[13] - Research and development expenses for the first three quarters of 2022 were ¥151,894,491.01, an increase from ¥119,364,029.14 in the same period of 2021[19] Product Development and Market Strategy - The company attributed the revenue growth to the expansion of its product line and effective control of domestic COVID-19, leading to a significant increase in sales[6] - The company reported a year-to-date net profit growth driven by increased sales of self-produced products and improved cost control[6] - The company plans to launch several new products in Q4 2022, including the fully automated coagulation analyzer CA5200 and the high-speed fully automated chemiluminescence analyzer MAGICL6200[13] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] Inventory and Operating Costs - The company’s inventory increased to approximately 376 million RMB, up from 252 million RMB in the previous year[16] - Total operating costs for the first three quarters of 2022 were ¥847,993,776.91, up 30.6% from ¥649,303,464.59 in the previous year[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,376[8] - Basic and diluted earnings per share for the third quarter of 2022 were both ¥0.93, compared to ¥0.50 in the same quarter of 2021[21]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[12]. - The company's operating revenue for the first half of the year reached ¥973,211,496.78, representing a 62.12% increase compared to ¥600,288,159.94 in the same period last year[20]. - Net profit attributable to shareholders increased by 93.03% to ¥329,801,726.74 from ¥170,856,236.75 year-on-year[22]. - The net profit after deducting non-recurring gains and losses rose by 107.68% to ¥324,746,556.32 compared to ¥156,371,441.63 in the previous year[22]. - The company's cash flow from operating activities increased by 13.80% to ¥139,398,475.54, up from ¥122,489,994.89 in the same period last year[22]. - Basic earnings per share rose by 91.17% to ¥0.65 from ¥0.34 year-on-year[21]. - The company's total assets grew by 10.35% to ¥3,462,750,351.49 from ¥3,137,931,357.50 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 9.76% to ¥2,311,900,340.42 from ¥2,106,400,196.02 at the end of the previous year[20]. - The company achieved operating revenue of 973.21 million yuan, a year-on-year increase of 62.12%[51]. - The revenue from in vitro diagnostic business was 831 million yuan, reflecting a significant growth of 90.04%[51]. - The company reported a total operating profit of ¥341,905,801.15 for the first half of 2022, up from ¥150,030,047.62 in the same period of 2021, representing a growth of about 128.5%[140]. Market Expansion and Product Development - User data indicated an increase in active users by 25%, reaching a total of 5 million users by June 30, 2022[12]. - The company plans to launch three new products in the next quarter, focusing on point-of-care testing (POCT) technology[12]. - Market expansion efforts include entering two new international markets, aiming for a 10% increase in overseas sales by the end of 2022[12]. - The company is actively expanding its product lines and pursuing overseas strategies, contributing to revenue growth[22]. - The company is actively promoting new projects in various diagnostic areas, including myocardial markers, inflammation, and tumor markers[36]. - The company is focusing on market expansion, targeting a 30% increase in market share in key regions over the next two years[176]. - A strategic acquisition was announced, which is expected to contribute an additional 500 million in revenue annually starting next fiscal year[178]. - The company is exploring potential mergers and acquisitions to enhance its market share and operational capabilities[168]. Research and Development - The company is investing RMB 100 million in R&D for new diagnostic technologies, with a focus on enhancing product accuracy and speed[12]. - R&D investment for the first half of 2022 was 116.16 million yuan, representing a year-on-year increase of 45.73% and accounting for 11.93% of operating revenue[47]. - The company has established seven major technology platforms, enhancing its core competitiveness in the in vitro diagnostic industry[46]. - The company is committed to enhancing its R&D capabilities, focusing on small and high-speed chemiluminescence instruments and comprehensive reagent support[44]. - The company is actively researching and developing products for emerging health threats, such as monkeypox, and has completed EU registration for these products[37]. - The company has obtained 53 new product registration certificates in the first half of 2022, bringing the total to 1,209, including 359 domestic and 850 foreign certificates[56]. Operational Efficiency - The company has established a dynamic capacity adjustment mechanism to respond quickly to market demand, ensuring timely order fulfillment and maintaining reasonable inventory levels[38]. - The company emphasizes cost control through optimized supply chain management and has achieved favorable procurement costs, enhancing overall product competitiveness[37]. - The company has a robust production model that combines sales forecasting with a make-to-order approach, ensuring efficient production and inventory management[38]. - The company has implemented a flexible sales model that combines distribution and direct sales, enhancing its ability to innovate and respond to clinical demands[40]. Financial Management and Shareholder Commitments - The company reported a net cash outflow from investing activities of ¥45,355,737.88, a significant decrease of 141.61% from a net inflow of ¥109,010,969.85 in the previous period[60]. - The company has established commitments to avoid any potential competition from its actual controller and related parties[103]. - The controlling shareholder has pledged not to transfer shares for 36 months post-IPO, with specific conditions for any future share reductions[96]. - The company will notify the public three trading days in advance of any share reduction plans, including quantity and price range[100]. - The commitments made by shareholders and senior management are subject to public supervision and regulatory oversight[102]. Environmental and Social Responsibility - The company reported that it does not belong to the key pollutant discharge units and has implemented appropriate measures for environmental protection[82]. - The wastewater generated by the company meets the Class 3 standard of the Comprehensive Wastewater Discharge Standard (GB8979-1996) after pretreatment[83]. - The company has installed an online monitoring system for wastewater discharge, ensuring compliance with environmental standards[83]. - The company donated 644,000 RMB to the University of Science and Technology of China for COVID-19 crisis management training for medical personnel and related patients[89].

编号：2022-001 证券代码：603387 证券简称：基蛋生物 基蛋生物科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------------|---------------------------------|------------------------------------------------------------------| | | | | | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | | | □媒体采访 ■业绩说明会 | | | | □新闻发布会 | □路演活动 | | | □现场参观 □一对一沟通 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称及人员 | 光大证券 | | | 姓名 | 浙商证券 | | | | 中信证券 | | | | 申万宏源证券 | | | | 华安证券等 | | | 时间 | 2022 年 4 月 28 日 | 15：00-16：00；16:30 — 17:30 | | 地点 | 线上交流 | | | 上市公司接待人员 | | 董事长苏恩本先生、财务总监倪文先生 ...